Compare Humana Inc (HUM) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs JPMorgan Chase & Co — how do they compare? Humana Inc trades at $398.55 (market cap $47.81B), while JPMorgan Chase & Co trades at $338.67 (market cap $900.78B). The key difference: JPMorgan Chase & Co is far larger — about 18.8× Humana Inc's market cap, and JPMorgan Chase & Co pays the higher dividend (1.77%). Which is the better fit depends on your goals.
| HUM | JPM | |
|---|---|---|
Market Cap | $47.81B | $900.78B |
Sector | Health | Financials |
52-Week High | $409.42 | $346.91 |
52-Week Low | $163.67 | $282.84 |
Enterprise Value | $56.85B | — |
Dividend Yield | 0.89% | 1.77% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
JPMorgan Chase trades at $341.10, down 0.6% on the day, with a bullish technical signal from moving averages and support at $339. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $169.4B in 2024 to $181.8B in 2025. Analyst consensus is Moderate Buy with a $374 price target, representing 9.6% upside potential. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings on April 14.
JPMorgan demonstrates solid fundamentals with consistent revenue growth and strong net income margins above 30%. The stock appears reasonably valued with a P/E of 14.6. Key risks include geopolitical tensions impacting banking operations and cybersecurity vulnerabilities from advanced AI systems. The bullish analyst sentiment and technical setup suggest potential for continued upside if earnings momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
